These questions have been submitted by folks on the mailing list and answered by Dr. Moll, Director of the Thrombophilia Program at the Carolina Cardiovascular Biology Center, Department of Medicine, Division of Hematology-Oncology, UNC Chapel Hill (North Carolina, USA). Why am I doing this?
Q1: Are there known side-effects after having been on Lovenox for over one year?
A1: Bleeding and possibly osteoporosis.
Q2: Is it possible to have a clot while on Lovenox, using the appropriate dosage level calculated against body weight?
A2: Yes, it is possible, but uncommon. New blood clots (recurrence of DVT or PE) occur in approximately 2-5 % of patients treated with full dose
LMWH.
Q3: When measuring the effectiveness of Lovenox, does one run a PTT?
A3: No. The PTT is only minimally prolonged by Lovenox and other low molecular weight heparins (= LMWHs) and is therefore not helpful. If one wants
to measure the effectiveness of LMWHs, one needs to obtain an "anti-Xa level" (= "heparin level").
Lovenox belongs to the group of "low molecular weight heparins" (= LMWHs). Several LMWHs are on the market. While they differ a little pharmacologically, clinically they are all more or less equally effective and safe. In the US the following LMWHs are available:
Outside the US the following LMWHs are also available: